Corona Remedies has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the stock exchanges, detailing its environmental, social, and governance (ESG) performance. The filing, made in accordance with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlights the company's strategic focus on sustainable manufacturing and ethical business practices. The report discloses a turnover of ₹1,403.18 crore and a net worth of ₹745.97 crore for the fiscal year.

Environmental Initiatives

The company has implemented a Zero Liquid Discharge (ZLD) mechanism at its Bhayla facility, utilizing an Effluent Treatment Plant with a processing capacity of 200 KLD. To reduce its carbon footprint, corona remedies has commissioned a 1.3 MW solar power plant at the Bhayla unit and invested in a 4.25 MW solar park. Additionally, the company has transitioned to LED lighting across its manufacturing facilities to lower electricity consumption.

Social and Governance Metrics

The company reported a total workforce of 5,153 permanent employees and 533 other than permanent employees for F.Y. 2025-26. Women constitute 13% of the Board of Directors and 20% of the Key Managerial Personnel. The report confirms that no human rights grievances or safety-related incidents were recorded during the year. The company maintains a 24/7 Occupational Health Centre and conducts periodic mock drills to ensure workplace safety.

Operational Overview

Corona Remedies operates as a B2C pharmaceutical entity, serving 22 states nationally and 18 countries internationally. Exports accounted for approximately 4.06% of the total turnover. The company focuses on therapeutic areas such as women’s healthcare, cardio-diabetes, and chronic therapies. It ranks fifth in its addressable women’s healthcare market according to Pharmatrac data for December 2025.

Financial and Regulatory Compliance

The company stated that it is compliant with all statutory requirements relevant to the National Guidelines on Responsible Business Conduct (NGRBC) principles. It has not received any adverse orders from regulatory authorities regarding anti-competitive conduct or product safety. The BRSR report has been uploaded to the company's website and forms part of the Annual Report for F.Y. 2025-26.

CORONA Remedies Limited will participate in an investor conference in London on June 15 and June 16, 2026, to engage with institutional investors. The meetings, organized by Kotak Institutional Equities, are scheduled to commence at 09:00 AM British Summer Time (BST) onwards. The company clarified that discussions during these sessions will be restricted to publicly available information, ensuring no unpublished price sensitive information (UPSI) is disclosed.

The conference will include both 1x1 meetings and group interactions. The disclosure was made to the stock exchanges in compliance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

CORONA Remedies noted that the schedule is subject to change due to exigencies on the part of the host or the company. The intimation has been made available on the company's official website.